Stakeholders say EMA's proposed pharmacovigilance fees are too high

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1431, 2012-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Stakeholders say EMA's proposed PV fees are too high

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 668, 2012-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

European pharma face pharmacovigilance fees

By  

Reactions Weekly, Vol. 1, Iss. 1422, 2012-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

European pharma face pharmacovigilance fees

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 664, 2012-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

What do Stakeholders Think about Pharmacovigilance?

By Edwards I. Ralph  

Drug Safety, Vol. 33, Iss. 8, 2010-08 ,pp. : 619-621

Adis International

Access to resources Recommend Favorite

The EMA's Pharmacovigilance Working Party (PhVWP) has concluded a review into the safety of blue dyes

By  

Reactions Weekly, Vol. 1, Iss. 1400, 2012-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite